{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:33:32Z","timestamp":1791232412976,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T00:00:00Z","timestamp":1529971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T00:00:00Z","timestamp":1529971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Myeloproliferative neoplasms (MPNs) are a leading cause of splanchnic vein thrombosis (SVT). SVT is observed in all MPNs and frequently affects young patients. Therapy should be addressed to three main goals: preventing thrombosis recurrence, managing the underlying MPN, and supporting liver dysfunction. Life-long oral anticoagulation with vitamin K antagonists is the cornerstone of the antithrombotic treatment. However, recurrences of SVT or other thrombosis may occur in 15\u201320% of patients. Direct oral anticoagulants can represent an alternative and preliminary data encourage comparative studies. Survival of patients with SVT in MPN is primarily influenced by the natural history of the underlying neoplasms, rather than the SVT event. An aggressive management is recommended and a treatment algorithm based on the different MPN subtypes is proposed. Hydroxyurea is the cytoreductive drug of choice in polycythemia vera and essential thrombocythemia, whereas ruxolitinib is indicated in intermediate and high-risk patients with myelofibrosis and in PV patients resistant or intolerant to hydroxyurea. The management of SVT in MPNs requires a multidisciplinary approach that may include a hematologist, a gastroenterologist, an interventional radiologist, and a surgeon. In the case of clinical deterioration despite pharmacological therapy, patients with SVT should be considered for invasive procedures or liver transplantation.<\/jats:p>","DOI":"10.1038\/s41408-018-0100-9","type":"journal-article","created":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T11:59:05Z","timestamp":1530014345000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018"],"prefix":"10.1038","volume":"8","author":[{"given":"Guido","family":"Finazzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"De Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziano","family":"Barbui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,26]]},"reference":[{"key":"100_CR1","doi-asserted-by":"publisher","first-page":"3685","DOI":"10.1182\/blood-2014-07-551515","volume":"124","author":"W Ageno","year":"2014","unstructured":"Ageno, W., Dentali, F. & Squizzato, A. How I treat splanchnic vein thrombosis. Blood 124, 3685\u20133691 (2014).","journal-title":"Blood"},{"key":"100_CR2","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.cgh.2009.09.019","volume":"8","author":"MR Thatipelli","year":"2010","unstructured":"Thatipelli, M. R., McBane, R. D., Hodge, D. O. & Wysokinski, W. E. Survival and recurrence in patients with splanchnic vein thromboses. Clin. Gastroenterol. Hepatol. 8, 200\u2013205 (2010).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"100_CR3","first-page":"99","volume":"40","author":"W Ageno","year":"2014","unstructured":"Ageno, W. et al. IRSVT Study Group. Antithrombotic treatment of splanchnic vein thrombosis: results of an international registry. Semin. Thromb. Hemost. 40, 99\u2013105 (2014).","journal-title":"Semin. Thromb. Hemost."},{"key":"100_CR4","doi-asserted-by":"publisher","first-page":"167","DOI":"10.7326\/0003-4819-151-3-200908040-00004","volume":"151","author":"S Darwish Murad","year":"2009","unstructured":"Darwish Murad, S. et al. EN-Vie (European Network for Vascular Disorders of the Liver). Etiology, management, and outcome of the Budd-Chiari syndrome. Ann. Intern. Med. 151, 167\u2013175 (2009).","journal-title":"Ann. Intern. Med."},{"key":"100_CR5","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1160\/th15-04-0326","volume":"115","author":"V De Stefano","year":"2016","unstructured":"De Stefano, V., Qi, X., Betti, S. & Rossi, E. Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment. Thromb. Haemost. 115, 240\u2013249 (2016).","journal-title":"Thromb. Haemost."},{"key":"100_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.103","volume":"6","author":"V De Stefano","year":"2016","unstructured":"De Stefano, V. et al. Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients. Blood Cancer J. 6, e493 (2016).","journal-title":"Blood Cancer J."},{"key":"100_CR7","doi-asserted-by":"publisher","first-page":"E61","DOI":"10.1002\/ajh.24993","volume":"93","author":"S Lavu","year":"2018","unstructured":"Lavu, S. et al. Splanchnic vein thrombosis in patients with myeloproliferative neoplasms: the Mayo clinic experience with 84 consecutive cases. Am. J. Hematol. 93, E61\u2013E64 (2018).","journal-title":"Am. J. Hematol."},{"key":"100_CR8","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/bjh.13080","volume":"167","author":"F Lussana","year":"2014","unstructured":"Lussana, F. et al. A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. Br. J. Haematol. 167, 541\u2013546 (2014).","journal-title":"Br. J. Haematol."},{"key":"100_CR9","doi-asserted-by":"publisher","first-page":"5617","DOI":"10.1182\/blood-2008-12-196014","volume":"113","author":"F Dentali","year":"2009","unstructured":"Dentali, F. et al. JAK2V617F mutation for the early diagnosis of Ph myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood 113, 5617\u20135623 (2009).","journal-title":"Blood"},{"key":"100_CR10","doi-asserted-by":"publisher","first-page":"4921","DOI":"10.1182\/blood-2011-09-376517","volume":"120","author":"JH Smalberg","year":"2012","unstructured":"Smalberg, J. H. et al. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood 120, 4921\u20134928 (2012).","journal-title":"Blood"},{"key":"100_CR11","doi-asserted-by":"crossref","unstructured":"Barbui, T. et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 8, 15 (2018).","DOI":"10.1038\/s41408-018-0054-y"},{"key":"100_CR12","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.leukres.2015.03.009","volume":"39","author":"U Gianelli","year":"2015","unstructured":"Gianelli, U. et al. Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis. Leuk. Res. 39, 525\u2013529 (2015).","journal-title":"Leuk. Res."},{"key":"100_CR13","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/S0168-8278(02)00434-8","volume":"38","author":"HL Janssen","year":"2003","unstructured":"Janssen, H. L. et al. Budd-Chiari syndrome: a review by an expert panel. J. Hepatol. 38, 364\u2013371 (2003).","journal-title":"J. Hepatol."},{"key":"100_CR14","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/j.1478-3231.2006.01269.x","volume":"26","author":"SK Sarin","year":"2006","unstructured":"Sarin, S. K. et al. Consensus on extra-hepatic portal vein obstruction. Liver Int. 26, 512\u2013519 (2006).","journal-title":"Liver Int."},{"key":"100_CR15","doi-asserted-by":"publisher","first-page":"e419S","DOI":"10.1378\/chest.11-2301","volume":"141","author":"C Kearon","year":"2012","unstructured":"Kearon, C. et al. American College of Chest Physicians. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141, e419S\u2013e496S (2012).","journal-title":"Chest"},{"key":"100_CR16","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1111\/j.1538-7836.2011.04484.x","volume":"9","author":"J Hoekstra","year":"2011","unstructured":"Hoekstra, J. et al. Long-term follow-up of patients with portal vein thrombosis and myeloproliferative neoplasms. J. Thromb. Haemost. 9, 2208\u20132214 (2011).","journal-title":"J. Thromb. Haemost."},{"key":"100_CR17","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1002\/lt.23443","volume":"18","author":"RH Westbrook","year":"2012","unstructured":"Westbrook, R. H. et al. Prevalence and clinical outcomes of the 46\/1 haplotype, Janus kinase 2 mutations, and ten-eleven translocation 2 mutations in Budd-Chiari syndrome and their impact on thrombotic complications post liver transplantation. Liver Transpl. 18, 819\u2013827 (2012).","journal-title":"Liver Transpl."},{"key":"100_CR18","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","volume":"149","author":"C Kearon","year":"2016","unstructured":"Kearon, C. et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149, 315\u2013352 (2016).","journal-title":"Chest"},{"key":"100_CR19","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1056\/NEJMoa025313","volume":"349","author":"AY Lee","year":"2003","unstructured":"Lee, A. Y. et al. Randomized comparison of low-molecular-weight heparin versus oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer (CLOT) investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N. Engl. J. Med. 349, 146\u2013153 (2003).","journal-title":"N. Engl. J. Med."},{"key":"100_CR20","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1001\/jama.2015.9243","volume":"314","author":"AYY Lee","year":"2015","unstructured":"Lee, A. Y. Y. et al. CATCH Investigators. Tinzaparin vs. warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. J. Am. Med. Assoc. 314, 677\u2013686 (2015).","journal-title":"J. Am. Med. Assoc."},{"key":"100_CR21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s11739-016-1398-6","volume":"11","author":"G Finazzi","year":"2016","unstructured":"Finazzi, G. & Ageno, W. Direct oral anticoagulants in rare venous thrombosis. Intern. Emerg. Med. 11, 167\u2013170 (2016).","journal-title":"Intern. Emerg. Med."},{"key":"100_CR22","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","volume":"378","author":"GE Raskob","year":"2018","unstructured":"Raskob, G. E. et al. Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N. Engl. J. Med. 378, 615\u2013624 (2018).","journal-title":"N. Engl. J. Med."},{"key":"100_CR23","doi-asserted-by":"publisher","first-page":"S172","DOI":"10.1016\/S0049-3848(16)30128-1","volume":"140","author":"A Young","year":"2016","unstructured":"Young, A. et al. OC-11\u2014anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Thromb. Res. 140, S172\u2013S173 (2016).","journal-title":"Thromb. Res."},{"key":"100_CR24","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1111\/liv.13285","volume":"37","author":"A De Gottardi","year":"2017","unstructured":"De Gottardi, A. et al. Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. Liver Int. 37, 694\u2013699 (2017).","journal-title":"Liver Int."},{"key":"100_CR25","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.mayocp.2017.10.007","volume":"93","author":"DT Janczak","year":"2018","unstructured":"Janczak, D. T. et al. Rivaroxaban and apixaban for initial treatment of acute venous thromboembolism of atypical location. Mayo Clin. Proc. 93, 40\u201347 (2018).","journal-title":"Mayo Clin. Proc."},{"key":"100_CR26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1208500","volume":"368","author":"R Marchioli","year":"2013","unstructured":"Marchioli, R. et al. Cardiovascular events and intensity of treatment in polycythemia vera. N. Engl. J. Med. 368, 22\u201333 (2013).","journal-title":"N. Engl. J. Med."},{"key":"100_CR27","doi-asserted-by":"publisher","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","volume":"121","author":"G Barosi","year":"2013","unstructured":"Barosi, G. et al. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood 121, 4778\u20134781 (2013).","journal-title":"Blood"},{"key":"100_CR28","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","volume":"32","author":"T Barbui","year":"2018","unstructured":"Barbui, T. et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia 32, 1057\u20131069 (2018).","journal-title":"Leukemia"},{"key":"100_CR29","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","volume":"122","author":"T Barbui","year":"2013","unstructured":"Barbui, T., Finazzi, G. & Falanga, A. Myeloproliferative neoplasms and thrombosis. Blood 122, 2176\u20132178 (2013).","journal-title":"Blood"},{"key":"100_CR30","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3324\/haematol.12053","volume":"93","author":"V De Stefano","year":"2008","unstructured":"De Stefano, V. et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica 93, 372\u2013380 (2008).","journal-title":"Haematologica"},{"key":"100_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0048-9","volume":"8","author":"V De Stefano","year":"2018","unstructured":"De Stefano, V. et al. Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. Blood Cancer J. 8, 25 (2018).","journal-title":"Blood Cancer J."},{"key":"100_CR32","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1111\/j.1365-2141.2009.08019.x","volume":"148","author":"G Barosi","year":"2010","unstructured":"Barosi, G. et al. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br. J. Haematol. 148, 961\u2013963 (2010).","journal-title":"Br. J. Haematol."},{"key":"100_CR33","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","volume":"112","author":"JJ Kiladjian","year":"2008","unstructured":"Kiladjian, J. J. et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 112, 3065\u20133072 (2008).","journal-title":"Blood"},{"key":"100_CR34","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1182\/blood-2012-07-442012","volume":"122","author":"A Quint\u00e1s-Cardama","year":"2013","unstructured":"Quint\u00e1s-Cardama, A. et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon \u03b1-2a. Blood 122, 893\u2013901 (2013).","journal-title":"Blood"},{"key":"100_CR35","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi, A. M. et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N. Engl. J. Med. 372, 426\u2013435 (2015).","journal-title":"N. Engl. J. Med."},{"key":"100_CR36","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","volume":"18","author":"F Passamonti","year":"2017","unstructured":"Passamonti, F. et al. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Lancet Oncol. 18, 88\u201399 (2017).","journal-title":"Lancet Oncol."},{"key":"100_CR37","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1056\/NEJMc1401255","volume":"371","author":"B Cassinat","year":"2014","unstructured":"Cassinat, B., Verger, E. & Kiladjian, J. J. Interferon alfa therapy in CALR-mutated essential thrombocythemia. N. Engl. J. Med. 371, 188\u2013189 (2014).","journal-title":"N. Engl. J. Med."},{"key":"100_CR38","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","volume":"121","author":"H Gisslinger","year":"2013","unstructured":"Gisslinger, H. et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood 121, 1720\u20131728 (2013).","journal-title":"Blood"},{"key":"100_CR39","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/sj.leu.2404473","volume":"21","author":"G Barosi","year":"2007","unstructured":"Barosi, G. et al. A unified definition of clinical resistance\/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. Leukemia 21, 277\u2013280 (2007).","journal-title":"Leukemia"},{"key":"100_CR40","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1182\/blood-2017-05-785790","volume":"130","author":"CN Harrison","year":"2017","unstructured":"Harrison, C. N. et al. Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. Blood 130, 1889\u20131897 (2017).","journal-title":"Blood"},{"key":"100_CR41","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1182\/blood-2017-02-765032","volume":"130","author":"S Verstovsek","year":"2017","unstructured":"Verstovsek, S. et al. Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. Blood 130, 1768\u20131771 (2017).","journal-title":"Blood"},{"key":"100_CR42","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1182\/blood-2017-08-802165","volume":"130","author":"G Finazzi","year":"2017","unstructured":"Finazzi, G. Ruxolitinib in ET: not all MPN are equal. Blood 130, 1873\u20131874 (2017).","journal-title":"Blood"},{"key":"100_CR43","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes, F. et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113, 2895\u20132901 (2009).","journal-title":"Blood"},{"key":"100_CR44","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","volume":"115","author":"F Passamonti","year":"2010","unstructured":"Passamonti, F. et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 115, 1703\u20131708 (2010).","journal-title":"Blood"},{"key":"100_CR45","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","volume":"29","author":"N Gangat","year":"2011","unstructured":"Gangat, N. et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J. Clin. Oncol. 29, 392\u2013397 (2011).","journal-title":"J. Clin. Oncol."},{"key":"100_CR46","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek, S. et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N. Engl. J. Med. 366, 799\u2013807 (2012).","journal-title":"N. Engl. J. Med."},{"key":"100_CR47","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison, C. et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N. Engl. J. Med. 366, 787\u2013798 (2012).","journal-title":"N. Engl. J. Med."},{"key":"100_CR48","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1038\/leu.2016.283","volume":"31","author":"M Marchetti","year":"2017","unstructured":"Marchetti, M. et al. Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations. Leukemia 31, 882\u2013888 (2017).","journal-title":"Leukemia"},{"key":"100_CR49","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/bjh.13379","volume":"170","author":"AJ Mead","year":"2015","unstructured":"Mead, A. J. et al. Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis:results of the UK ROBUST Trial. Br. J. Haematol. 170, 29\u201339 (2015).","journal-title":"Br. J. Haematol."},{"key":"100_CR50","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.3324\/haematol.2016.143677","volume":"101","author":"HK Al-Ali","year":"2016","unstructured":"Al-Ali, H. K. et al. Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial. Haematologica 101, 1065\u20131073 (2016).","journal-title":"Haematologica"},{"key":"100_CR51","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/ajh.24614","volume":"92","author":"L Pieri","year":"2017","unstructured":"Pieri, L. et al. Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms. Am. J. Hematol. 92, 187\u2013195 (2017).","journal-title":"Am. J. Hematol."},{"key":"100_CR52","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1002\/hep.28466","volume":"63","author":"C Noronha Ferreira","year":"2016","unstructured":"Noronha Ferreira, C. et al. Natural history and management of esophagogastric varices in chronic noncirrhotic, nontumoral portal vein thrombosis. Hepatology 63, 1640\u20131650 (2016).","journal-title":"Hepatology"},{"key":"100_CR53","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1038\/leu.2015.233","volume":"92","author":"NM Kr\u00f6ger","year":"2015","unstructured":"Kr\u00f6ger, N. M. et al. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT\/ELN international working group. Leukemia 92, 2126\u20132133 (2015).","journal-title":"Leukemia"},{"key":"100_CR54","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1200\/JOP.2016.013268","volume":"12","author":"N Farhadfar","year":"2016","unstructured":"Farhadfar, N., Cerquozzi, S., Patnaik, M. & Tefferi, A. Allogeneic hematopoietic stem-cell transplantation for myelofibrosis: a practical review. J. Oncol. Pract. 12, 611\u2013621 (2016).","journal-title":"J. Oncol. Pract."},{"key":"100_CR55","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1002\/1097-0142(19911115)68:10<2310::AID-CNCR2820681034>3.0.CO;2-2","volume":"68","author":"G Barosi","year":"1991","unstructured":"Barosi, G. et al. An atypical myeloproliferative disorder with high thrombotic risk and slow disease progression. Cancer 68, 2310\u20132318 (1991).","journal-title":"Cancer"},{"key":"100_CR56","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.leukres.2013.09.008","volume":"38","author":"G Barosi","year":"2014","unstructured":"Barosi, G. et al. Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: a consensus-based SIE, SIES, GITMO position paper. Leuk. Res. 38, 55\u201360 (2014).","journal-title":"Leuk. Res."},{"key":"100_CR57","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1111\/liv.12816","volume":"35","author":"A Potthoff","year":"2015","unstructured":"Potthoff, A. et al. Long-term outcome of liver transplant patients with Budd-Chiari syndrome secondary to myeloproliferative neoplasms. Liver Int. 35, 2042\u20132049 (2015).","journal-title":"Liver Int."},{"key":"100_CR58","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/TP.0b013e3182247b05","volume":"92","author":"S Chinnakotla","year":"2011","unstructured":"Chinnakotla, S. et al. Long-term follow-up of liver transplantation for Budd-Chiari syndrome with antithrombotic therapy based on the etiology. Transplantation 92, 341\u2013345 (2011).","journal-title":"Transplantation"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0100-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0100-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0100-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T11:36:01Z","timestamp":1671536161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0100-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,26]]},"references-count":58,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,7]]}},"alternative-id":["100"],"URL":"https:\/\/doi.org\/10.1038\/s41408-018-0100-9","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,26]]},"assertion":[{"value":"3 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"64"}}